 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
2-14-2024
Insider Buy |
Bakker Juliet Tammenoms
|
$50.83
CAGR »
|
$406,672.80
8,000 shares |
2-10-2023
Insider Buy |
Bakker Juliet Tammenoms
Director |
$12.50
CAGR »
|
$6,000,000.00
480,000 shares |
8-5-2021
Insider Buy |
Eric Weinberg
Chief Commercial Officer |
$16.47
CAGR »
|
$15,235.28
925 shares |
8-5-2021
Insider Buy |
Ilya Goldshleger
Chief Operating Officer |
$14.03
CAGR »
|
$33,274.88
2,372 shares |
8-3-2021
Insider Buy |
Julie Andrews
Director |
$16.00
CAGR »
|
$250,000.00
15,625 shares |
8-5-2021
Insider Buy |
Ronald M. Kurtz, M.D.
See Remarks |
$15.94
CAGR »
|
$2,050,378.30
128,638 shares |
8-3-2021
Insider Buy |
Eric Weinberg
Chief Commercial Officer |
$16.00
CAGR »
|
$500,000.00
31,250 shares |
8-3-2021
Insider Buy |
Jesse Anderson Corley
Director |
$16.00
CAGR »
|
$1,250,000.00
78,125 shares |
8-3-2021
Insider Buy |
Bakker Juliet Tammenoms
Director |
$16.00
CAGR »
|
$10,200,000.00
637,500 shares |
8-3-2021
Insider Buy |
Robert Keith Warner
Director |
$16.00
CAGR »
|
$700,000.00
43,750 shares |
Also See: Institutional Holders of RXST
Also See: SEC filings
Below we present the annualized performance delivered by Rxsight stock since 2-14-2024 (the date of the most recent
insider purchase). The performance of the investment from the time Rxsight insider buying occurred is the ultimate
test of whether insiders were right about RXST being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/15/2024 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$53.55 |
|
| End price/share: |
$52.77 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-1.46% |
|
| Annualized Gain: |
-7.60% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$9,854.00 |
|
| Years: |
0.19 |
|
Rxsight Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Rxsight insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding RXST
|
|
Free RXST Email Alerts:
